肿瘤微环境
免疫疗法
癌症
免疫系统
癌症免疫疗法
CD8型
免疫检查点
免疫抑制
医学
T细胞
PD-L1
免疫学
癌症研究
内科学
作者
Chenchen Zhao,Yuanwei Pan,Lujie Liu,Jing Zhang,Xianjia Wu,Yu Liu,Xingzhong Zhao,Lang Rao
出处
期刊:Small
[Wiley]
日期:2024-03-08
卷期号:20 (31)
被引量:6
标识
DOI:10.1002/smll.202311702
摘要
Abstract The PD1/PD‐L1 immune checkpoint blocking is a promising therapy, while immunosuppressive tumor microenvironment (TME) and poor tumor penetration of therapeutic antibodies limit its efficacy. Repolarization of tumor‐associated macrophages (TAMs) offers a potential method to ameliorate immunosuppression of TME and further boost T cell antitumor immunity. Herein, hybrid cell membrane biomimetic nanovesicles (hNVs) are developed by fusing M1 macrophage‐derived nanovesicles (M1‐NVs) and PD1‐overexpressed tumor cell‐derived nanovesicles (PD1‐NVs) to improve cancer immunotherapy. The M1‐NVs promote the transformation of M2‐like TAMs to M1‐like phenotype and further increase the release of pro‐inflammatory cytokines, resulting in improved immunosuppressive TME. Concurrently, the PD1‐NVs block PD1/PD‐L1 pathway, which boosts cancer immunotherapy when combined with M1‐NVs. In a breast cancer mouse model, the hNVs efficiently accumulate at the tumor site after intravenous injection and significantly inhibit the tumor growth. Mechanically, the M1 macrophages and CD8 + T lymphocytes in TME increase by twofold after the treatment, indicating effective immune activation. These results suggest the hNVs as a promising strategy to integrate TME improvement with PD1/PD‐L1 blockade for cancer immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI